Vincerx Pharma, Inc. (VINC)
| Market Cap | 78.51K +194.1% |
| Revenue (ttm) | n/a |
| Net Income | -22.65M |
| EPS | -8.98 |
| Shares Out | 5.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177 |
| Open | 0.0150 |
| Previous Close | 0.0150 |
| Day's Range | 0.0150 - 0.0150 |
| 52-Week Range | 0.0051 - 0.0257 |
| Beta | 1.51 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Vincerx Pharma
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 d... [Read more]
Financial Performance
Financial StatementsNews
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
Revised Potential Distribution Range of $0.03 to $0.07 per share based on current estimates and assumptions
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on July 16, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on July 7, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders Failure to approve Dissolution Proposal will reduce or eliminate any potential distribution...
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on June 18, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on June 6, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Quarterly report: Q1 2025
Vincerx Pharma has published its Q1 2025 quarterly earnings report on May 14, 2025.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on May 12, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on April 30, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma announces plan to delist from Nasdaq
Vincerx Pharma (VINC) announced its intention to file a Form 25 Notification of Delisting with the SEC on or about April 28, which will remove Vincerx’s common stock from listing…
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025
Vincerx Pharma Inc trading resumes
16:35 EDT Vincerx Pharma (VINC) Inc trading resumes
Vincerx terminates letter of intent with Global Digital, initiates wind down
Vincerx Pharma (VINC) announced that it has terminated the previously announced non-binding letter of intent with Global Digital Holdings, conducting business as QumulusAI, regarding a potential merge...
Vincerx Pharma Inc trading halted, news pending
16:01 EDT Vincerx Pharma (VINC) Inc trading halted, news pending
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global...
Vincerx Pharma Registration statement: Registration Filing
Vincerx Pharma filed a registration statement on March 31, 2025, providing details about a securities offering with the SEC.
Vincerx Pharma Annual report: Q4 2024
Vincerx Pharma has published its Q4 2024 annual report on March 27, 2025.
Vincerx Pharma Inc trading resumes
09:15 EDT Vincerx Pharma (VINC) Inc trading resumes
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
Vincerx Pharma (VINC) has entered into a non-binding letter of intent with Global Digital Holdings conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company...
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings I...
Vincerx Pharma Inc trading halted, news pending
08:40 EDT Vincerx Pharma (VINC) Inc trading halted, news pending
Vincerx Pharma Inc trading resumes
16:35 EST Vincerx Pharma (VINC) Inc trading resumes
Vincerx Pharma announces termination of reverse merger term sheet
Vincerx Pharma (VINC) announced that the previously signed binding Term Sheet between Vincerx, Oqory, and Vivasor for a reverse merger transaction has been terminated. As a result, the board of…
Vincerx Pharma Inc trading halted, news pending
16:00 EST Vincerx Pharma (VINC) Inc trading halted, news pending